Every 8-K that Alnylam Pharmaceuticals, Inc. (ALNY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALNY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALNY filings page.
Alnylam Pharmaceuticals reported strong second-quarter 2026 results, with total revenues of $1,290,948 thousand, up 67% from Q2 2025. Net product revenues were $1,172,109 thousand, a 74% increase, led by AMVUTTRA and ONPATTRO TTR therapies generating $1,030,223 thousand, an 89% rise.
GAAP income from operations was $231,441 thousand versus a prior-year loss, and GAAP net income reached $164,494 thousand, while non-GAAP net income was $251,801 thousand and diluted non-GAAP EPS was $1.84. Cash, cash equivalents and marketable securities totaled $3.3 billion as of June 30, 2026, supported by net cash inflows from operating activities.
The company updated 2026 guidance to $4,200–$4,500 million in TTR net product revenues and $4,700–$5,100 million in total net product revenues. Expected 2026 net revenues from collaborations and royalties were raised to $575–$625 million, and non-GAAP R&D and SG&A expense guidance of $2,700–$2,800 million was reiterated.
Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members, appointing Benjamin F. Cravatt, Ph.D. as a Class III director effective June 1, 2026, with a term running until the 2028 annual stockholder meeting. He will also join the Board’s Science and Technology Committee.
As a non-employee director, Dr. Cravatt will receive a $75,000 annual cash retainer and an initial stock option grant with a $600,000 grant date fair value, vesting in three equal annual installments, with an exercise price set at the common stock closing price on the grant date.
The filing also reports results of the 2026 annual meeting. As of the March 25, 2026 record date, 133,427,910 common shares were outstanding. Stockholders re-elected three Class I directors, approved on an advisory basis the compensation of named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026.
Alnylam Pharmaceuticals reported a very strong first quarter of 2026, driven by its transthyretin (TTR) franchise. Total revenues nearly doubled to $1.17 billion, with net product revenues of $1.04 billion, up 121% from the same quarter in 2025.
The company swung from a GAAP net loss of $18.3 million in Q1 2025 to GAAP net income of $206.0 million, and non‑GAAP net income rose to $273.0 million. AMVUTTRA generated $889.9 million in sales, and total TTR net product revenues reached $910.4 million, a 153% increase. Rare disease products GIVLAARI and OXLUMO added $125.7 million, up 15%.
Alnylam reiterated its full‑year 2026 guidance, including total net product revenues of $4.9–$5.3 billion and non‑GAAP R&D and SG&A expenses of $2.7–$2.8 billion, while highlighting broad pipeline progress and upcoming clinical readouts in the second half of 2026.
Alnylam Pharmaceuticals reported that its board granted a special, fully performance-based equity award to CEO Yvonne Greenstreet under the 2018 Stock Incentive Plan. The award targets 55,373 performance share units, with a face value of $18.0 million based on the $325.07 share price on the grant date.
The units can vest only if the company’s stock achieves demanding average price hurdles between $500 and $800 over a 30‑day period before December 31, 2029, allowing 50% to 200% of target shares to vest. If the stock does not reach $500, the award is forfeited. Continued service is generally required, with modified treatment for certain terminations and change in control events.
Alnylam Pharmaceuticals reported a strong turnaround for 2025, driven by rapid growth in its RNAi medicines. Total revenues reached $3.71 billion, up 65% from 2024, while net product revenues rose 81% to $2.99 billion, led by AMVUTTRA for ATTR amyloidosis and steady growth in GIVLAARI and OXLUMO.
The company moved from a GAAP net loss of $278.2 million in 2024 to GAAP net income of $313.7 million in 2025; non-GAAP net income was $683.6 million. Fourth-quarter 2025 revenues were $1.10 billion, up 85% year over year, with total net product revenues more than doubling.
Management introduced its "Alnylam 2030" strategy, highlighting durable TTR leadership and long-term innovation, and issued 2026 guidance calling for $4.9–$5.3 billion in net product revenues and $400–$500 million in collaboration and royalty revenue. Cash, cash equivalents and marketable securities were $2.91 billion at year-end, supporting continued pipeline and manufacturing investments.
Alnylam Pharmaceuticals reported preliminary 2025 global net product revenues of approximately $2,987 million for its four marketed RNAi medicines, with fourth-quarter revenues of about $995 million. Alongside these early figures, the company introduced a new five-year strategy called “Alnylam 2030”, which is intended to guide its next phase of growth. Alnylam also shared its product and pipeline goals for 2026 and issued full-year 2026 combined net product revenue guidance, with final audited 2025 results to follow in February 2026.
Alnylam Pharmaceuticals (ALNY) announced its financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details.
The information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Alnylam Pharmaceuticals reported a material event on an Form 8-K that discloses a Credit Agreement dated September 30, 2025 among Alnylam, the lenders party to the agreement, and Bank of America, N.A. acting as Administrative Agent. The filing references an interactive cover page data file embedded within the Inline XBRL document and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. No loan amounts, interest terms, covenants, maturity dates, or other economic details are included in the provided text.
Alnylam Pharmaceuticals, Inc. filed an 8-K reporting a material event related to a Convertible Note Offering. The filing references press releases issued on September 8, 2025 and September 9, 2025
The submission also notes inclusion of the cover page interactive data file in Inline XBRL and is signed by Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer. The filing does not disclose terms, amounts, or use of proceeds for the convertible notes within the provided text.
Alnylam Pharmaceuticals announced significant organizational changes with the combination of its Research and Early Development function and Development function into a single R&D organization. Key leadership appointments include:
- Dr. Pushkal Garg promoted to Executive VP, Chief Research and Development Officer with new compensation package: - Base salary: $825,000 - Annual incentive target: 65% of base salary - Long-term equity incentives to be determined
- Dr. Kevin Fitzgerald (Executive VP, Chief Scientific Officer) receives expanded responsibilities for external innovation with: - Increased annual incentive target to 60% of base salary - One-time restricted stock unit grant valued at $2.5M, vesting over 3 years
This strategic reorganization aims to streamline R&D operations and strengthen the company's innovation capabilities. The changes were approved by the People, Culture and Compensation Committee on June 12, 2025, with formal announcement made on June 18, 2025.